Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer

被引：0
|
作者：
M Gijsen
P King
T Perera
P Parker
B Larijani
A Harris
A Kong
机构：
[1] University of Oxford,Cancer Research UK
[2] Johnson & Johnson Pharmaceutical Research & Development,undefined
[3] London Research Institute,undefined
来源：
Breast Cancer Research | / 12卷
关键词：
Breast Cancer; Trastuzumab; Feedback Loop; Xenograft Model; Fluorescence Resonance Energy Transfer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers
    Takeda, Tatsuaki
    Yamamoto, Hiromasa
    Suzawa, Ken
    Tomida, Shuta
    Miyauchi, Shunsaku
    Araki, Kota
    Nakata, Kentaro
    Miura, Akihiro
    Namba, Kei
    Shien, Kazuhiko
    Soh, Junichi
    Shien, Tadahiko
    Kitamura, Yoshihisa
    Sendo, Toshiaki
    Toyooka, Shinichi
    CANCER SCIENCE, 2020, 111 (03) : 849 - 856
  • [32] Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
    Singer, Christian F.
    Tan, Yen Y.
    Fitzal, Florian
    Steger, Guenther G.
    Egle, Daniel
    Reiner, Angelika
    Rudas, Margaretha
    Moinfar, Farid
    Gruber, Christine
    Petru, Edgar
    Bartsch, Rupert
    Tendl, Kristina A.
    Fuchs, David
    Seifert, Michael
    Exner, Ruth
    Balic, Marija
    Bago-Horvath, Zsuzsanna
    Filipits, Martin
    Gnant, Michael
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3676 - 3683
  • [33] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Marcia R. Campbell
    Hui Zhang
    Shabnam Ziaee
    Ana Ruiz-Saenz
    Nathaniel Gulizia
    Julie Oeffinger
    Dhara N. Amin
    Deepika Ahuja
    Mark M. Moasser
    Catherine C. Park
    Breast Cancer Research and Treatment, 2016, 155 : 431 - 440
  • [34] A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
    Lee-Hoeflich, Si Tuen
    Crocker, Lisa
    Yao, Evelyn
    Pham, Thinh
    Munroe, Xander
    Hoeflich, Klaus P.
    Sliwkowski, Mark X.
    Stern, Howard M.
    CANCER RESEARCH, 2008, 68 (14) : 5878 - 5887
  • [35] Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
    Cocco, Emiliano
    Carmona, F. Javier
    Won, Helen H.
    Berger, Michael F.
    Hyman, David M.
    Rossi, Valentina
    Chan, Carmen
    Moriarty, Alyssa
    Papadopoulos, Kyriakos P.
    Wick, Michael J.
    Cownie, James
    Sarotto, Ivana
    Cutler, Richard E.
    Avogadri-Connors, Francesca
    Savas, Peter
    Lalani, Alshad S.
    Boni, Valentina
    Loi, Sherene
    Baselga, Jose
    Montemurro, Filippo
    Scaltriti, Maurizio
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [36] Cellular senescence within HER2-amplified breast cancer: Potential implications for breast cancer immune surveillance and HER2-targeted therapy resistance
    Thaler, Sonja
    Schad, Arno
    Kirkpatrick, Charles James
    Sleeman, Jonathan P.
    Springer, Erik
    Schmidt, Marcus
    Cotarelo, Cristina L.
    CANCER RESEARCH, 2018, 78 (04)
  • [37] HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
    Sampera, Aida
    Javier Sanchez-Martin, Francisco
    Arpi, Oriol
    Visa, Laura
    Iglesias, Mar
    Menendez, Silvia
    Gaye, Elisabeth
    Dalmases, Alba
    Clave, Sergi
    Gelabert-Baldrich, Mariona
    Poulsen, Thomas Tuxen
    Kragh, Michael
    Bellosillo, Beatriz
    Albanell, Joan
    Rovira, Ana
    Montagut, Clara
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (11) : 2135 - 2145
  • [38] BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer
    Sampson, E. L.
    Valero, V.
    Roche, H.
    Pienkowski, T.
    Canon, J.
    Zhao, Y.
    Carney, W.
    Mackey, J.
    Taupin, H.
    Lindsay, M.
    Buyse, M.
    Slamon, D.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A34 - A34
  • [39] BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer
    Valero, V.
    Roche, H.
    Pienkowski, T.
    Canon, J.
    Zhao, Y.
    Carney, W.
    Mackey, J.
    Taupin, H.
    Buyse, M.
    Slamon, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Campbell, Marcia R.
    Zhang, Hui
    Ziaee, Shabnam
    Ruiz-Saenz, Ana
    Gulizia, Nathaniel
    Oeffinger, Julie
    Amin, Dhara N.
    Ahuja, Deepika
    Moasser, Mark M.
    Park, Catherine C.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 431 - 440
12345